| F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections | Frank Vinluan | 08/12/20 | Europe |
| Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug | Sarah de Crescenzo | 09/17/19 | San Diego |
| As Drug Resistance Grows, Amplyx Tests New Antifungal Drug | Sarah de Crescenzo | 04/15/19 | San Diego |
| Raising $56M, Revolution Medicines Drops Old Work and Turns to Cancer | Frank Vinluan | 04/24/18 | San Francisco |
| Bio Roundup: Trump Backlash, Verdine Plans, Sarepta Sale & More | Alex Lash | 02/24/17 | National |
| Cidara Antifungal Flunks in Phase 2 Clinical Trial, Sinking Shares | Frank Vinluan | 02/21/17 | San Diego |
| Former Cubist CEO Mike Bonney Joins Third Rock Ventures | Alex Lash | 01/07/16 | Boston |
| West Coast Biotech Roundup: CRISPR, Doudna, Aduro, Amgen, NEA & More | Alex Lash | 04/16/15 | San Francisco |
| Big Day For Biotech IPOs as Aduro More Than Doubles In Price | Alex Lash | 04/15/15 | San Francisco |
| Third Rock’s New Revolution Looks to Squeeze More Drugs From Nature | Alex Lash | 02/04/15 | San Francisco |
| With $32M, Boston Anti-Fungal Startup Morphs Into San Diego’s Cidara | Bruce V. Bigelow | 06/30/14 | San Diego |
